5-HT2A receptors are important targets of many second-generation antipsychotics. Blocking them can alter interactions between serotonin and dopamine pathways. This has been proposed as one contributor to the lower movement-related risk of some receptor profiles, although it does not prevent all adverse effects from D2 blockade.<\/p>\n
Serotonin is a neurotransmitter that acts through several receptor families in the brain and body. It influences many functions, including mood, sleep, appetite and sensory processing. Its role cannot be reduced to happiness, and different receptor actions can produce very different physiological or clinical effects even within the same medicine.<\/p>\n
The ratio of laboratory binding affinities is not a complete explanation of atypicality or effectiveness. Risperidone, for example, can still produce movement problems and prolactin elevation despite substantial serotonin receptor effects. Pimavanserin acts mainly through 5-HT2A inverse agonism and antagonism in its specific clinical indication, demonstrating that the receptor can have therapeutic relevance outside conventional D2 blockade. These observations should not be generalised to every condition. Clinical evidence must establish the benefits and harms of each medicine rather than assume that strong 5-HT2A binding guarantees a particular outcome.<\/p>\n
Inverse agonism and antagonism are related but distinct ways of limiting receptor activity. Pimavanserin is an example of a medicine whose 5-HT2A action is central to its proposed mechanism in Parkinson’s disease psychosis. Its specific indication matters: evidence for one population does not establish equivalent efficacy in schizophrenia or make serotonin targeting interchangeable with other antipsychotic strategies.<\/p>\n
Further reading:<\/strong> DailyMed prescribing information (1)<\/a>; Research record 8935801<\/a>; DailyMed prescribing information (3)<\/a>; DailyMed prescribing information (4)<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":" 5-HT2A receptors are important targets of many second-generation antipsychotics. Blocking them can alter interactions between serotonin and dopamine pathways. This has been proposed as one contributor to the lower movement-related risk of some receptor profiles\u2026Continue Reading<\/a><\/span><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[38],"class_list":["entry","author-","has-excerpt","post-693","post","type-post","status-publish","format-standard","category-causes-and-biology","tag-serotonin"],"brizy_media":[],"_links":{"self":[{"href":"https:\/\/schizophrenia.world\/index.php?rest_route=\/wp\/v2\/posts\/693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/schizophrenia.world\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/schizophrenia.world\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/schizophrenia.world\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=693"}],"version-history":[{"count":0,"href":"https:\/\/schizophrenia.world\/index.php?rest_route=\/wp\/v2\/posts\/693\/revisions"}],"wp:attachment":[{"href":"https:\/\/schizophrenia.world\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/schizophrenia.world\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/schizophrenia.world\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}